Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

已保存。查看收藏列表。 Processa Pharmaceuticals, Inc.（纳斯达克股票代码：PCSA）的首席商务和战略官Patrick ...

David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his ...

根据最近的SEC文件显示，Processa Pharmaceuticals, Inc. (NASDAQ: PCSA )研发部门总裁David Young最近增加了他在公司的持股。Young以每股0.7975美元的价格购买了124,500股普通股，交易总额为99,288美元。这次购买使Young的直接持股增加到205,405股。

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused ...

Processa Pharmaceuticals (PCSA) announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s ...

Processa Pharmaceuticals, Inc. has successfully completed a public offering, raising $5 million to support its development of next-generation chemotherapeutic drugs aimed at improving efficacy and ...

Processa Pharmaceuticals, Inc. announced the pricing of a public offering aimed at raising approximately $5 million, with participation from its CEO, board members, and institutional investors.

HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.